¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚÎÒÃÇ ¤™
-
¿Æ¼¼´´Ð ¤™
-
²úÆ·ÓëÒµÎñ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°Òµ·¢Õ¹ ¤™
¼ò
¤™
- ÂýÐÔÉöÔಡ£¨CKD£©ÊÇÎÒ¹ú³£¼ûµÄÂýÐÔ¼²²¡Ö®Ò»£¬¶øÓÉÆäÒýÆðµÄ²¢·¢Ö¢¡ª¡ªÉöÐÔƶѪ£¬¸üÊÇÑÏÖØÓ°Ï컼ÕßÉú»îÖÊÁ¿Ó볤ÆÚ½¡¿µ×´¿ö[1]¡£
- ÔÚ¸ÄÉÆÈ«ÇòÉöÔಡԤºó×éÖ¯£¨KDIGO£©½üÈÕÕýʽ·¢²¼µÄ2026 °æ¡¶KDIGO ÂýÐÔÉöÔಡƶѪ¹ÜÀíÁÙ´²Êµ¼ùÖ¸ÄÏ¡·ÖУ¬ÈÔÍƼöºìϸ°ûÉú³É´Ì¼¤¼Á£¨ESAs£©¶ø·ÇȱÑõÓÕµ¼Òò×Ó-¸¬°±õ£ôÇ»¯Ã¸ÒÖÖƼÁ£¨HIF-PHIs£©×÷ΪÉöÐÔƶѪ»¼ÕßµÄÒ»ÏßÖÎÁÆ·½°¸[2]¡£
- Óë³£¼ûµÄ¡°´ÙºìËØ¡±Õë¼Á²»Í¬£¬ÓɵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄ´´ÐµÏÍþ¹ú¼ÊÅàĪɳëÄ×¢ÉäÒº£¨ÉÌÆ·Ãû£ºÊ¥ÂÞÀ³?£©ÊÇÒ»ÖÖ³¤Ð§ESAs£¬Ò²ÊÇÄ¿Ç°ÉöÐÔƶѪÁìÓòÈ«ÇòΨһÉÏÊеÄС·Ö×ÓëÄÀ໯ѧµÏÍþ¹ú¼ÊÎÇÒÿÔ½öÐèƤÏÂ×¢ÉäÒ»´Î[3]£¬¼´¿É³¤Ð§¡¢Æ½ÎȵØÌáÉýѪºìµ°°×ˮƽ¡£
´«Í³µÄÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ£¨rHuEPO£©ÊÇͨ¹ý»ùÒò¹¤³ÌºÏ³ÉµÄÉúÎïÖƼÁ£¬Æä½á¹¹ÓëÈËÌåÄÚÌìÈ»´æÔڵĴٺìϸ°ûÉú³ÉËØ£¨EPO£©¸ß¶ÈÀàËÆ[1]¡£¶øÅàĪɳëĵĵ®ÉúÔòµÃÒæÓÚÒ»Ïîŵ±´¶û½±»ñ½±¼¼Êõ¡ª¡ªÊɾúÌåչʾ¼¼Êõ£¨phage display£©[9]¡£¿ÆÑÐÈËԱͨ¹ý¸Ã¼¼Êõ£¬´ÓÊɾúÌåչʾëÄ¿âÖÐɸѡ³öÄÜÓëÈËÌåEPOÊÜÌå½ôÃܽáºÏµÄС·Ö×ÓëÄ£¬ÔÙ¾¹ý¾ÛÒÒ¶þ´¼£¨PEG£©ÐÞÊΣ¬×îÖÕÐγÉÁËȫнṹµÄÅàĪɳëÄ¡£
ÓÉÓÚÆä°±»ùËáÐòÁÐÓëÈËÌåÄÚÔ´ÐÔEPOÍêÈ«²»Í¬£¬Òò´Ë¿ÉÒÔ±ÜÃâ½»²æÃâÒß·´Ó¦£¬½µµÍÒòʹÓÃÍâÔ´ÐÔEPO¿ÉÄܵ¼Öµġ°´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔƶѪ£¨PRCA£©¡±·çÏÕ[5]¡£
¶ÌЧrHuEPOͨ³£ÐèÒª½øÐÐƵ·±×¢É䣬¸ø»¼Õß´øÀ´²»±ã£¬²»ÀûÓÚÉöÐÔƶѪµÄ³¤ÆÚ¹ÜÀí¡£ÅàĪɳëIJÉÓÃÈý´ú·ÖÖ§ÐÍPEGÐÞÊμ¼Êõ£¬Äܹ»ÓÐЧÑÓ³¤°ëË¥ÆÚÖÁ70Сʱ×óÓÒ[3]£¬´Ó¶øÑÓ³¤¸øµÏÍþ¹ú¼Ê¼ä¸ô¡£
È»¶ø£¬ÅàĪɳëĵij¤Ð§×÷Óò¢²»½ö½öÊÇÓÉÓÚ°ëË¥ÆÚÑÓ³¤¡£ÓÐÑо¿ÏÔʾ£¬ÓërHuEPOºÍ´ïÒÀ²´Í¡¦ÁÏà±È£¬ÅàĪɳëÄÄܹ»Óë¾ßÓдٺì×÷ÓõÄEPOÊÜÌåÐγɸ߶ÈÎȶ¨Çҳ־õĽáºÏ£¬ÆäÔÚEPOÊÜÌåÉϵÄÖÍÁôʱ¼äԼΪrHuEPOµÄ6.4¡«6.8±¶£¬²¢¿Éͨ¹ýά³Öϸ°û±íÃæEPOÊÜÌåµÄ±í´ï£¬Î¬³ÖÏÂÓÎÐźÅͨ·³ÖÐø¼¤»îÒÔÉú³Éºìϸ°û¡£¶¯ÎïʵÑéºÍÁ½ÏîIIÆÚÁÙ´²ÊÔÑéҲ֤ʵÁËÅàĪɳëľßÓеÏÍþ¹ú¼Ê´ú¶¯Á¦Ñ§£¨PK£©ºÍµÏÍþ¹ú¼ÊЧѧ£¨PD£©Ë«ÑÓ³¤Ð§Ó¦£¬ÇÒÄÍÊÜÐÔÁ¼ºÃ[10]£¬´Ó¶øΪÅàĪɳëĵij¤Ð§´Ùºìϸ°ûÉú³É×÷ÓÃÌṩÁËÀíÂÛÒÀ¾Ý¡£
2025Äê·¢²¼µÄ¡¶Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶¡·Ã÷È·Ö¸³ö£¬Ê¹ÓðëË¥ÆÚ³¤µÄµÏÍþ¹ú¼ÊÎÈçÅàĪɳëĵȳ¤Ð§ÖƼÁ£©¿É¼õÉÙ×¢Éä´ÎÊý¡¢Ìá¸ßÖÎÁÆÒÀ´ÓÐÔ[6]¡£
͸ÎöÈËȺÖÐÁÆЧ´ïµ½·ÇÁÓЧÐÔÖյ㣬ÉõÖÁÕ¹ÏÖ³ö¸üÓÅÇ÷ÊÆ
¡¶ÁøÒ¶µ¶¡·×Ó¿¯EClinicalMedicine·¢±íµÄÒ»ÏîÕë¶Ô¶ÌЧrHuEPO¾ÖεÄ͸ÎöƶѪ»¼ÕßµÄËæ»ú¡¢¿ª·ÅÐÔ¡¢ÑôÐÔ¶ÔÕÕ¡¢·ÇÁÓЧÐÔ¢óÆÚÊÔÑéÑо¿£¬ÄÉÈëÀ´×ÔÖйúµÄ43¼ÒÑо¿ÖÐÐĹ²372Àý»¼Õߣ¬Ëæ»ú2£º1·ÖÅäÖÁÅàĪɳëÄ×é»ò¶ÌЧrHuEPO×é¡£½á¹ûÏÔʾ£¬ÅàĪɳëÄ×éѪºìµ°°×£¨Hb£©Ë®Æ½´Ó»ùÏßÖÁÁÆЧÆÀ¹ÀÆÚµÄƽ¾ù±ä»¯Îª0.07£¨0.92£©g/dL£¬rHuEPO×éΪ-0.22£¨0.97£©g/dL£¬×é¼ä²îÒìΪ0.29 g/dL£¨95%CI£º0.11¡«0.47£©¡£±íÃ÷ÅàĪɳëÄÔÚÖ÷ÒªÁÆЧÖյ㷽Ãæ·ÇÁÓЧÓÚrHuEPO¡£´ËÍ⣬ÖÃÐÅÏÞÏÂÏÞ£¨0.11£©¸ßÓÚÁ㣬±íÃ÷ÅàĪɳëÄÔÚÁÆЧÉϾßÓиüÓŵÄÇ÷ÊÆ[11]¡£
ÃÀ¹úÉöÔàѧ»á£¨ASN£©2024Äê»á·¢±íµÄÒ»Ïî͸ÎöÈËȺIIIÆÚʺó·ÖÎö½á¹ûÏÔʾ£¬Ïà±ÈrHuEPO£¬ÅàĪɳëÄʹ¸ü¶àµÄ»¼ÕßHbˮƽά³ÖÔÚ11~13g/dL£¨57.5% vs 36.8%£¬P=0.0002£©µÄÄ¿±ê·¶Î§[12]¡£¼´Ê¹°´ÕÕHbˮƽ¡Ý10g/dLÀ´Í³¼Æ´ï±êÂÊ£¬ÅàĪɳëÄ×éÈÔÂÔ¸ßÓÚrHuEPO×飨91.8% vs 88.6%£©[13]¡£
·Ç͸ÎöÈËȺÖÐÁÆЧ¸üÏÔÖø£¬ÀÏÄê¡¢Éö¹¦ÄܽϲîÑÇ×éÓÈΪͻ³ö
¡¶ÉöÔà¹ú¼Ê±¨¸æ¡·£¨Kidney International Reports£©·¢±íµÄÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©¡¢ÑôÐÔ¶ÔÕÕ¡¢·ÇÁÓЧÐÔ¢óÆÚÁÙ´²Ñо¿£¬¹²ÄÉÈëÀ´×Ô¹úÄÚ38¸öÖÐÐĵÄ173Àýδ½ÓÊܹýESAsÖÎÁƵķÇ͸ÎöCKDƶѪ»¼Õߣ¬ÆÀ¹ÀÅàĪɳëĶԱȶÌЧrHuEPOÖÎÁÆ52ÖܵÄÁÆЧºÍ°²È«ÐÔ¡£½á¹ûÏÔʾ£¬ÅàĪɳëÄ×éÁÆЧÆÀ¹ÀÆÚHb×Ô»ùÏßƽ¾ùÉý¸ß19.2 g/L£¬rHuEPO×éÔòƽ¾ùÉý¸ß15.4 g/L£¬Á½×é²îÒìΪ3.8 g/L£¨95% CI£¬0.7¡«6.9£¬P = 0.02£©£¬´ïµ½Ô¤ÉèµÄ·ÇÁÓ±ê×¼[14]¡£
ÊÀ½çÉöÔಡ´ó»á£¨WCN£©2025´ó»áÉÏ·¢²¼µÄÒ»ÏîÕë¶Ô·Ç͸ÎöÈËȺIIIÆÚÑо¿µÄʺó·ÖÎöÏÔʾ£¬Ïà±ÈrHuEPO×飬ÅàĪɳëÄ×éHbˮƽ×Ô»ùÏßÖÁÁÆЧÆÀ¹ÀÆÚ£¨16~24ÖÜ£©µÄÉý¸ß¸üΪÏÔÖø£¨1.920 vs 1.542 g/dL£¬P=0.0163£©£¬ÓÈÆäÔÚÀÏÄê¡¢»ùÏßeGFR½ÏµÍµÈÑÇ×黼ÕßÖÐÁÆЧ¸üΪͻ³ö¡£¸ÃÑо¿»¹·¢ÏÖ£¬Ïà±ÈrHuEPO£¬ÅàĪɳëĶÔÌú´úлӰÏì½ÏС£¬¶Ô²¹ÌúµÄÐèÇó¸üµÍ[15]¡£
ÐÄѪ¹Ü²»Á¼Ê¼þ·çÏÕµÍ
Õë¶Ô͸ÎöÈËȺºÍ·Ç͸ÎöÈËȺµÄIIIÆÚÑо¿Öоù·¢ÏÖ£¬ÅàĪɳëÄ×éµÄ¸´ºÏ°²È«ÐÔʼþ£¨°üÀ¨È«ÒòËÀÍö¡¢×äÖкÍÐļ¡¹£ËÀ£©ºÍÆäËûÐÄѪ¹Üʼþ£¨°üÀ¨ÐèҪסԺÖÎÁƵIJ»Îȶ¨ÐĽÊÍ´ºÍÐèҪסԺÖÎÁƵÄÐÄÁ¦Ë¥½ß£©·¢ÉúÂÊÔÚÊýÖµÉϾùµÍÓÚrHuEPO×é[10,13]¡£Õë¶Ô͸ÎöÈËȺµÄIIIÆÚÑо¿Êºó·ÖÎö»¹ÏÔʾ£¬ÅàĪɳëÄ×éµÄ¸ßѪѹ¡¢¸Î¶¾ÐԺ͸߼ØѪ֢·¢ÉúÂÊÔÚÊýÖµÉÏÒ²¾ùµÍÓÚrHuEPO×é[12]¡£
ASN 2025·¢±íµÄÕë¶ÔÁ½ÏîIIIÆÚÁÙ´²Ñо¿µÄʺó·ÖÎöÏÔʾ£¬ÔÚ͸Îö»¼ÕßÖУ¬ÅàĪɳëÄÏà±ÈrHuEPO¶ÔÕÕ×éµÄ5P-MACE£¨°üÀ¨ÐÄѪ¹ÜËÀÍö¡¢Ðļ¡¹£ËÀ¡¢×äÖС¢²»Îȶ¨ÐÔÐĽÊÍ´¼°ÐèסԺµÄÐÄÁ¦Ë¥½ß£©·çÏÕϽµ65%£¨HR 0.35£¬95%CI 0.11-1.10£©£¬·Ç͸Îö»¼ÕßÖÐÔòÏà±È¶ÔÕÕ×éϽµ86%£¨HR 0.14£¬95%CI 0.02-1.28£©[13]¡£ÌáʾÅàĪɳëÄÏà±È´«Í³¶ÌЧrHuEPO¾ßÓнµµÍÐÄѪ¹Üʼþ·çÏÕµÄDZÔÚ»ñÒæ¡£
Ò»Ïî»úÖÆÑо¿´Óϸ°û²ãÃæ֤ʵÁËÅàĪɳëĵÄÁ¼ºÃÐÄѪ¹Ü°²È«ÐÔ¿ÉÄÜÓëÆä¶ÔEPOÊÜÌåµÄÑ¡ÔñÐÔÓйء£¸ÃÑо¿·¢ÏÖÅàĪɳëÄÄܹ»ÒÖÖÆEPOR-CD131Òì¶þ¾ÛÌåÐγɣ¬×è¶ÏJAK2/STAT3ÐźÅͨ·µÄ¼¤»î£¬´Ó¶ø¼õÇáÄò¶¾Ö¢¶¾ËØÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó£¬·¢»ÓÐÄÔà±£»¤×÷ÓÃ[16]¡£
ÁÙ´²ÑÖ¤ÒÀ¾Ý±íÃ÷£¬Ê¥ÂÞÀ³?×÷ΪȫÇòΨһÉÏÊеÄС·Ö×ÓëÄÀàÉöÐÔƶѪÖÎÁƵÏÍþ¹ú¼ÊÎÎÞÂÛÔÚ͸Îö»ò·Ç͸ÎöÈËȺÖУ¬¾ù±íÏÖ³öÓÅÒìµÄÁÆЧÓëÁ¼ºÃµÄ°²È«ÐÔ£¬²¢Õ¹ÏÖ³öDZÔÚµÄÐÄѪ¹Ü±£»¤ÓÅÊÆ¡£ÆäÿÔÂÒ»´Î¸øµÏÍþ¹ú¼Ê½«ÓÐÖúÌáÉý»¼ÕßÒÀ´ÓÐԺ͸ÄÉƳ¤ÆÚ½á¹û£¬ÖúÁ¦»¼Õß»ñµÃ¸ü½¡¿µ¡¢¸üÓÐ×ðÑϵÄÉú»î¡£
²Î¿¼ÎÄÏ×£º
1. ÖйúÉöÐÔƶѪÕïÖÎÁÙ´²Êµ¼ùÖ¸ÄÏ[J]. ÖлªÒ½Ñ§ÔÓÖ¾,2021,101(20):1463-1502.
2. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1S):S1¨CS99.
3. ÅàĪɳëÄ×¢ÉäҺ˵Ã÷Ê飨ÐÞ¸ÄÈÕÆÚ£º2024Äê04ÔÂ03ÈÕ£©
4. ¹ú¼ÒµÏÍþ¹ú¼Ê¼à¾ÖÅú×¼ÅàĪɳëÄ×¢ÉäÒºÉÏÊÐ. https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20230630195113151.html£¨·¢²¼Ê±¼ä£º2023-06-30£©
5. ³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔƶѪÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.
6. Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶(2024°æ)[J]. ÖйúѪҺ¾»»¯,2025,24(1):1-12.
7. ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2025,41(6):455-488.
8. ÖйúΧ͸ÎöÆÚÂýÐÔÉöÔಡ¹ÜÀíÁÙ´²Êµ¼ùÖ¸ÄÏ£¨2025Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2025,41(10):788-810.
9. Lancet Gastroenterology & Hepatology.2018(3):820
10. Ma X, Li Z, Zhang L, et al. Overview of preclinical and phase II clinical studies on Pegmolesatide's long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction. J Transl Med. 2025;23(1):144.
11. Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28; 65:102273
12. Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888
13. Chen Jianghua, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Renal Anemia: Post Hoc Analysis of Two Phase 3 Trials. ASN 2025. Abstract: FR-PO0199
14. Xie J, Yang A, Qiu H£¬et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024 Dec 6;10(3):720-729.
15. Xueqing Yu,et al. Pegmolesatide for the Treatment of Anemia in Non-dialysis-dependent Chronic Kidney Disease Patients: Post-hoc Analysis of a Phase 3 Trial. WCN 2025. Abstract No: WCN25-679.
16. Zhang X, Li S, Lin T, et al. Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway. Int Immunopharmacol. 2025;167:115643.
¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
